News & Evens

2022-04-07

Congratulations! BiOptic's Analysis Software has certified by IEC 62304!

BiOptic Inc., as a biotechnology company with R&D, manufacturing, and marketing momentum. To extend the product market to clinical related fields, we followed all software develop guidelines for BiOptic instrument products and has been certified by FDA 21 CFR Part 11.
2022-02-17

BiOptic Inc., Giant Bio Technology Inc. and National Taiwan Ocean University have jointly publised a journal article on MDPI

According to the 2018 market survey report, the global farmed shrimp market is about 28 billion U.S. dollars. Due to the globalization and high-density of aquaculture industry, the spread of diseases has accelerated. Among them, shrimp infectious diseases will outbreak every few years, including white Spot disease (WSD), acute hepatopancreatic necrosis disease (AHPND), and hepatopancreatic microsporidia (HPM), which reduce the industry profit with an estimated $7.8 billion annually.
2021-12-28

BiOptic Inc. was listed on Taiwan’s Emerging Stock Board from Q4, 2021

BiOptic Inc.’s self-developed COVID-19 test kit has been formally submitted to the European Union a few days ago to apply for in vitro diagnostic medical device (CE-IVD) certification. After review and approval, it can be marketed and sold in the European Union.
2021-11-30

Congratulations! BiOptic has won the 20th Pharmaceutical Technology Research & Development Award- Golden Award

The “20th Pharmaceutical Technology Research and Development (PTRD) Award” is the only award which authorized by dual central agency including the Ministry of Health and Welfare and the Ministry of Economic Affairs in Taiwan.
2021-11-22

Congratulations! BiOptic has won the 28th Taiwan Small and Medium Enterprises Innovation Award!

BiOptic has won the 28th Taiwan Small and Medium Enterprises Innovation Award for its "Qsep1-Lite Bio-Fragment Analyzer" from Ministry of Economic Affairs, R.O.C.
2021-02-19

BiOptic has certificated by UL in conformance with FDA 21 CFR Part 11

The software system of Qsep series bio-fragment analyzer, Q-Analyzer, which is developed by BiOptic, has certificated by UL in conformance with FDA 21 CFR Part 11 in Jan 2021. The FDA guidelines for Data Integrity include the requirement for compliance for the storage of electronic records.
2021-01-22

BiOptic - Surveillance Pooling Test models

The Centers for Disease Control and Prevention (CDC) in the US has suggested a monitoring method - surveillance pooling test, which divides a large group into several small groups, and the samples of each group are mixed into one sample for testing and analysis; if a positive result has shown up in a group, the members of this group will conduct further tests individually. This method got the advantages of testing large groups with a small number of samples and at a lower cost, which is very suitable for schools, factories, communities, companies, and other units. The suggested testing process is continuously every 1 to 2 days, in order to find out the COVID-19 carrier and take steps before the situation worsens.
2021-01-14

ON-DEMAND WEBINAR: Rapid, Automated and High-Resolution Nucleic Acid Quality Control Solutions for Next-Generation Sequencing (NGS) using Capillary Electrophoresis (CE) approach

BiOptic will show how Qsep series bio-fragment analyzer support researchers on quality check during the NGS workflow by using capillary electrophoresis (CE) approach.
2020-12-16

Office Relocation Notice

Thanks for the efforts of our distributors all over the world. Although COVID-19 crushes the world economy, BiOptic is still growing while facing this pandemic. Due to the increasing number of orders, our production efficiency almost reaches its limit, so we decided to enlarge the space of our production line to fulfill the market demand. The headquarter of BiOptic Inc. will be relocated to the next building beside our existing ones from 12/19 to 12/20.
2020-11-13

BiOptic Inc. won A+ Industrial Innovation R&D Program

Congratulations! BiOptic won the A+ Industrial Innovation R&D Program